Q
Quoin Pharmaceuticals, Ltd. (QNRX)
NCM – Real Time Price. Currency in USD
6.07
-0.21 (-3.34%)
At close: May 12, 2026, 4:00 PM EDT
5.96
-0.11 (-1.73%)
Pre-market: May 13, 2026, 5:21 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.07
-0.21 (-3.34%)
At close: May 12, 2026, 4:00 PM EDT
5.96
-0.11 (-1.73%)
Pre-market: May 13, 2026, 5:21 AM EDT
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, CEO & Chairman |
| Ms. Denise Carter | Co-Founder, COO & Director |
| Ms. Sally Lawlor | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | qnrx-20260331x10q.htm |
| 2026-03-26 | 10-K | qnrx-20251231x10k.htm |
| 2026-03-11 | 8-K | tm268576d1_8k.htm |
| 2026-01-20 | 8-K | tm263667d1_8k.htm |
| 2025-12-02 | CORRESP | filename1.htm |
| 2025-11-17 | 8-K | tm2531454d1_8k.htm |
| 2025-11-12 | 8-K | tm2530990d1_8k.htm |
| 2025-11-07 | S-3 | tm2530425d1_s3.htm |
| 2025-11-06 | 8-K | tm2530187d1_8k.htm |
| 2025-10-23 | D |